8-K current report · filed Nov 12, 2026

Eledon Pharmaceuticals, Inc. (ELDN) 8-K Current Report: November 12, 2026

Item 2.02Item EX-99.1ELDN overview

Short answer

Eledon Pharmaceuticals, Inc. (ELDN) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers Eledon’s quarter ended September 30, 2026.

Eledon Pharmaceuticals, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Press release covers Eledon’s quarter ended September 30, 2026
  • Exhibit 99.1 contains the company’s quarterly financial results and management commentary

Item EX-99.1 · Exhibit EX-99.1

  • Q3 2026 revenue-free biotech posted a $21.0M operating loss excluding warrant revaluation, highlighting continued cash burn ahead of Phase 3
  • Cash, equivalents and short-term investments $69.7M, funding operations into Q2 2027 but likely requiring additional financing afterward
  • Global Phase 3 LEGACY kidney-transplant trial targeted for Q4 2026, expected enrollment approximately 600 patients
  • FDA Fast Track for kidney transplantation and IND clearance for an islet-transplant registrational study reduce regulatory friction for tegoprubart
  • Phase 2 data showed eGFR 71 vs 58 mL/min/1.73m² at month 24 and zero vs seven rejection events versus tacrolimus, supporting differentiation but requiring Phase 3 validation

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Eledon Pharmaceuticals, Inc. 8-K filings

Get the next ELDN 8-K as it lands

Follow ELDN for push alerts, or ask the research agent what this filing means.